

EHA 2024 Congress

June 13–16, 2024
Madrid, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association 2024 Hybrid Congress, the AML Hub Steering Committee members have provided their recommendations of the top abstracts to look out for in AML.

EHA 2024: Top abstracts in AML

June 13–16, 2024

Friday, June 14, 2024

Abstract	Title	Speaker	Time (CEST)
S130 View	The novel menin inhibitor ZE63-0302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations	Erin Hertlein	14:45–15:00
S131 View	Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal AUGMENT-101 phase 2 study	Ibrahim Aldoss	15:00–15:15
S132 View	First-in-human phase 1/2 study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: Updated results from dose escalation	Naval Daver	15:15–15:30
S133 View	A phase 1b study of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia with alterations in KMT2A or NPM1	Andrew H. Wei	15:30–15:45
S134 View	Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: Interim results of dose escalation from the Beat AML consortium	Joshua Zeidner	15:45–16:00

Saturday, June 15, 2024

Abstract	Title	Speaker	Time (CEST)
S135 View	Venetoclax-based salvage treatment for relapsed/refractory AML using a combination with high-dose cytarabine and mitoxantrone (HAM-VEN): Updated results of the phase-I/II SAL RELAX trial	Leo Ruhnke	11:30–11:45
S136 View	FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed/refractory (RR) AML	Wei-Ying Jen	11:45–12:00
S138 View	Magrolimab vs placebo in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: The ENHANCE-3 study	Naval Daver	12:15–12:30
S139 View	Phase 1/2 study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia	Alex Bataller	12:30–12:45

S102 View	First results of the APOLLO trial: A randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia	Uwe Platzbecker	15:15–15:30
S141 View	A post hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes who received oral azacitidine maintenance therapy in the QUAZAR AML-001 study	Maria Teresa Voso	16:45–17:00
S142 View	QuANTUM-First: Efficacy in newly diagnosed patients with fms-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy	Mikkael A. Sekeres	17:00–17:15
S144 View	Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort	Jorge Cortes	17:30–17:45
S265 View	Final long-term follow-up results of the RELAZA2 study: Azacitidine to treat measurable- residual disease in MDS and AML patients	Anne Sophie Kubasch	16:30–16:45

Sunday, June 16, 2024

Abstract	Title	Speaker	Time (CEST)
LB3444 View	Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low-risk myeloid malignancies: Results from EVI-2, a randomized, placebo-controlled phase 2 study	Stine Ulrik Mikkelsen	11:00–11:15
S146 View	Completed dose escalation from the first-in-human, phase 1/2 study of CD123 NK cell engager, SAR443579, in relapsed or refractory acute myeloid leukemia or high risk-myelodysplasia	Sylvain Garciaz	11:45–12:00
S148 View	Genomic landscape of adult AML with t(8;21) (q22;q22.1) and prognostic implications – results from the HARMONY platform	Alberto Hernandez-Sanchez	12:15–12:30
S149 View	Mini-consolidations versus intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A study from the DATAML and SAL registries	Christian Récher	12:30–12:45

Posters

Abstract	Title	Speaker
P536 View	Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia study	Jorge Cortes
P540 View	Safety and activity of revumenib in combination with fludarabine/ cytarabine (FLA) in patients with relapsed/refractory acute leukemias	Neerav Shukla

P560 View	Impact of TP53 mutations in patients with acute myeloid leukemia (AML) during oral azacitidine maintenance therapy: Outcomes from the QUAZAR AML-001 trial	Andrew H. Wei
P561 View	Gilteritinib plus venetoclax, low-dose cytarabine, and actinomycin D as first salvage therapy for relapsed or refractory FLT3 mutated acute myeloid leukemia	Andrius Žučenka
P565 View	FLAG regimen, combined with gemtuzumab (FLAG-GO) results in better optimal molecular response and outcomes, compared to combination with idarubicin (FLAG-IDA) in untreated core binding factor AML	Gautam Borthakur
P600 View	RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: Preliminary results from two ongoing studies	Dominik Chraniuk
P603 View	Phase II study of cladribine, idarubicin, and higher dose cytarabine (CLIA) in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML)	Tapan Kadia
P623 View	Reduced dose FLAG-mitoxantrone and low dose venetoclax induces deep remissions and high rate of transition to successful allogeneic stem cell transplantation in relapsed/refractory AML	Ahmad Ibrahim
P571 View	Real-world use of oral-azacitidine as maintenance therapy for acute myeloid leukemia in remission: Characteristics and outcomes of a French patient population	Christian Récher
P573 View	Prognostic relevance of TP53 mutations with or without concomitant complex karyotype in patients treated with CPX-351: Evidence from a large real-world Italian study.	Elisabetta Todisco
P1377 View	Long term efficacy results of the SIERRA trial: A phase 3 study of 131I-apamistamab-led allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, R/R AML	James M Foran
P1786 View	Pregnancy outcomes in patients with acute leukemia diagnosed at different gestation ages: A more than 30 years national research group for the treatment of acute leukemia experience	Vera Troitskaya
P1792 View	Time to hematologic recovery is a critical determinant of complete remission as a surrogate for overall survival after intensive chemotherapy for acute myeloid leukemia	Rithin Nedumannil
P1805 View	Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada	Brian Leber
P1810 View	Real-world use of first-line midostaurin in FLT3-mutated acute myeloid leukemia: A multicentric study from the Grupo Português de Leucemias Agudas	Joana Infante
P1818 View	The role of allo-HSCT in AML CR1 patients with MRD negativity after the first induction course	Elena Parovichnikova



EHA 2024

Follow us on X to keep up to date
with the latest from the congress

@AML_Hub

#EHA2024

View all @AML_Hub tweets from #EHA2024



AMLHub

Brought to you by

